Surface CD88 functionally distinguishes the MCTC from the MCT type of human lung mast cell.

Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA 23298, USA.
Journal of Allergy and Clinical Immunology (Impact Factor: 11.25). 07/2005; 115(6):1162-8. DOI: 10.1016/j.jaci.2005.02.022
Source: PubMed

ABSTRACT MC(T) and MC(TC) types of human mast cells (MCs) are distinguished from one another on the basis of the protease compositions of their secretory granules, but their functional and developmental relationships have been uncertain.
These studies better define the functional properties and developmental relationship of MC(T) and MC(TC) cells.
Mast cells were dispersed from human skin and lung, purified with anti-Kit antibody, and separated into CD88+ and CD88- populations by cell sorting. These cells were evaluated by immunocytochemistry with antitryptase and antichymase mAbs; for chymase and tryptase mRNA by real-time RT-PCR; for conversion of MC(T) to MC(TC) cells during cell culture with recombinant human stem cell factor and recombinant human IL-6; and for degranulation and leukotriene C 4 (LTC 4 ) secretion when stimulated with anti-FcepsilonRI, substance P, C5a, and compound 48/80.
Mature MC(T) and MC(TC) cells were separated from one another on the basis of selective expression of CD88, the C5aR, on MC(TC) cells. Lung MC(T) cells had negligible levels of chymase mRNA and retained their MC(T) phenotype in culture. Mature MC(TC) cells from skin and lung degranulated in response to FcepsilonRI cross-linking, C5a, compound 48/80, and substance P. Lung MC(TC) cells released LTC 4 on activation, but no LTC 4 was detected when skin-derived MC(TC) cells were activated. MC(T) cells from lung degranulated and released LTC 4 in response to anti-FcepsilonRI and substance P, but not to C5a and compound 48/80.
These observations functionally distinguish MC(T) from MC(TC) types of human mast cells and suggest important differences that may affect their participation in diseases such as asthma and urticaria.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Mast cells (MC) are ubiquitous resident cells, traditionally viewed as effector cells of allergic reactions that can store and synthesize de novo many mediators upon activation by a variety of stimuli. Exciting new insights are unveiling MC involvement in the pathogenesis of connective tissue disorders including wound healing and fibrosis. Abnormal wound repair is associated with an increased number of MC strategically located around blood vessels. Therapeutic local manipulation of MC population and reactivity may help improve and even prevent impaired repair processes for which there is no cure. Chymase, a MC-restricted protease, is pre-stored in MC cytoplasmic granules with other mediators. The development of a highly specific inhibitor targeting chymase established its pivotal effect on fibrosis pathogenesis in a mouse model of silica-induced fibrosis. This novel finding evokes the potential therapeutic relevance of chymase inhibition to prevent aberrant wound healing. MC are increased in number in a variety of fibrotic diseases, compared to normal scars. Chymase has become a rising target prompting the development of chymase-specific inhibitors to be used as prophylactic or therapeutic agents. Another emerging strategy may consist in evaluating the efficacy of mast cell stabilizing drugs such as cromolyn in abnormal wound healing-drugs which are already approved for human use in other MC-driven disorders. Limited treatment success of dysregulated wound healing underscores the need for novel targets be considered such as MC and/or MC-derived mediators and the necessity to design new therapeutic strategies for wounds that remain difficult to treat.
    Advances in wound care. 02/2012; 1(1):23-28.
  • Source
    Acta histochemica et cytochemica official journal of the Japan Society of Histochemistry and Cytochemistry 07/2014; · 1.22 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Mast cells (MC) are found in all vascularized tissues at homeostasis and, until recently, were viewed only as effector cells of allergic reactions via degranulation, the canonical process through which MC release mediators, including histamine and pre-formed proteases and cytokines such as TNF. Cross-linking of IgE bound to surface high affinity receptors for IgE (FcɛRI) by a specific antigen (Ag) triggers signaling events leading to degranulation. We and others have reported the concomitant production and export of an influential multifaceted sphingolipid mediator, sphingosine-1-phosphate (S1P) transported outside of MC by ATP-binding cassettes (ABC) transporters, i.e., independently of degranulation. Indeed, the MC horizon expanded by the discovery of their unique ability to selectively release mediators depending upon the stimulus and receptors involved. Aside from degranulation and transporter usage, MC are also endowed with piecemeal degranulation, a slower process during which mediator release occurs with minor morphological changes. The broad spectrum of pro- and anti-inflammatory bioactive substances MC produce and release, their amounts and delivery pace render these cells bona fide fine-tuners of the immune response. In this viewpoint article, MC developmental, phenotypic and functional plasticity, its modulation by microRNAs and its relevance to immunity, inflammation and cancer will be discussed.
    Molecular Immunology 04/2014; · 3.00 Impact Factor

Full-text (2 Sources)

Available from
Aug 21, 2014